About Microba
Microba is a company based in Brisbane (Australia) founded in 2017 by Gene Tyson.. Microba has raised $2.85 million across 3 funding rounds from investors including NIH, Macrogen and Sonic Healthcare. Microba has completed 1 acquisition, including Invivo Healthcare. Microba offers products and services including MetaPanel, MetaXplore, Analysis Platform, Discovery Platform, and Therapeutic Platform. Microba operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Brisbane, Australia
- Founders Gene Tyson
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Microba Life Sciences Limited
-
Annual Revenue
$10.23 M (USD)29.6as on Jun 30, 2025
-
Net Profit
$-9.76 M (USD)25.07as on Jun 30, 2025
-
EBITDA
$-13.18 M (USD)15.83as on Jun 30, 2025
-
Total Equity Funding
$2.85 M (USD)
in 3 rounds
-
Latest Funding Round
$9.35 M (USD), Post-IPO
Jun 23, 2025
-
Investors
NIH
& 2 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Microba
Microba is a publicly listed company on the ASX with ticker symbol MAP in Australia, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Microba
Microba offers a comprehensive portfolio of products and services, including MetaPanel, MetaXplore, Analysis Platform, Discovery Platform, and Therapeutic Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Next-generation test for gastrointestinal health diagnostics.
Platform for microbiome exploration and health insights.
End-to-end solution for microbiome data processing.
Databank for identifying microbiome-disease relationships.
System for developing microbial leads for chronic diseases.
Unlock access to complete
Unlock access to complete
Funding Insights of Microba
Microba has successfully raised a total of $2.85M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $9.35 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $9.3M
-
First Round
First Round
(12 Jun 2019)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2025 | Amount | Post-IPO - Microba | Valuation |
investors |
|
| Jun, 2023 | Amount | Grant - Microba | Valuation |
investors |
|
| Jun, 2019 | Amount | Series A - Microba | Valuation | Macrogen |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Microba
Microba has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, Macrogen and Sonic Healthcare. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location | |
|
Next-generation sequencing and genomics services are provided globally.
|
Founded Year | Domain | Location | |
|
Chain of pathology and radiology labs
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Microba
Microba has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Invivo Healthcare. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of microbiome tests and supplements to support human microbiome
|
2007 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Microba
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Microba Comparisons
Competitors of Microba
Microba operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Microba
Frequently Asked Questions about Microba
When was Microba founded?
Microba was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is Microba located?
Microba is headquartered in Brisbane, Australia. It is registered at Brisbane, Queensland, Australia.
Who is the current CEO of Microba?
Blake Wills is the current CEO of Microba.
Is Microba a funded company?
Microba is a funded company, having raised a total of $2.85M across 3 funding rounds to date. The company's 1st funding round was a Series A of $2.85M, raised on Jun 12, 2019.
What is the annual revenue of Microba?
Annual revenue of Microba is $10.23M as on Jun 30, 2025.
What does Microba do?
Microba was founded in 2017 in Brisbane, Australia, within the biotechnology sector focused on microbiome research. A drug discovery platform is operated, where human data and informatics methods are applied to link microbial genotypes with human phenotypes. Therapeutic pipelines are advanced for inflammatory bowel disease and immuno-oncology applications, supporting targeted medical advancements.
Who are the top competitors of Microba?
Microba's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Microba offer?
Microba offers MetaPanel, MetaXplore, Analysis Platform, Discovery Platform, and Therapeutic Platform.
Is Microba publicly traded?
Yes, Microba is publicly traded on ASX under the ticker symbol MAP.
How many acquisitions has Microba made?
Microba has made 1 acquisition, including Invivo Healthcare.
Who are Microba's investors?
Microba has 3 investors. Key investors include NIH, Macrogen, and Sonic Healthcare.
What is Microba's ticker symbol?
The ticker symbol of Microba is MAP on ASX.